Get the Stockscreener App
114.63
1.28%
-1.49
After Hours:
114.00
-0.63
-0.55%
Jazz Pharmaceuticals Plc stock is traded at $114.63, with a volume of 510.26K.
It is down -1.28% in the last 24 hours and up +8.02% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$116.12
Open:
$114.8
24h Volume:
510.26K
Relative Volume:
0.57
Market Cap:
$6.94B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
16.15
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-2.86%
1M Performance:
+8.02%
6M Performance:
-7.83%
1Y Performance:
+3.97%
1-Day Range:
$114.11
$116.56
1-Week Range:
$114.11
$118.72
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
114.63 | 7.03B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
C-suite shuffles ripple through pharma - PharmaVoice
Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating - Insider Monkey
10 Most Undervalued Foreign Stocks to Buy According to Analysts - Insider Monkey
What makes Jazz Pharmaceuticals plc stock price move sharplyCommunity Verified Stock Suggestions Drive Volume - metal.it
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline - Yahoo Finance
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Fund Update: Boston Trust Walden Corp added 229,885 shares of JAZZ PHARMACEUTICALS PLC ($JAZZ) to their portfolio - Quiver Quantitative
Is Jazz Pharmaceuticals plc a growth stock or a value stockDiscover high-impact stocks for growth - jammulinksnews.com
What are analysts’ price targets for Jazz Pharmaceuticals plc in the next 12 monthsBeginner Investor Opportunities To Watch Now - jammulinksnews.com
How volatile is Jazz Pharmaceuticals plc stock compared to the marketMaximize portfolio growth with strategic plans - jammulinksnews.com
What is the dividend policy of Jazz Pharmaceuticals plc stockGet alerts on the hottest market movers - jammulinksnews.com
What catalysts could drive Jazz Pharmaceuticals plc stock higher in 2025Rapid capital growth - jammulinksnews.com
Is Jazz Pharmaceuticals plc stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
Is it the right time to buy Jazz Pharmaceuticals plc stockCapitalize on market momentum for profits - jammulinksnews.com
When is Jazz Pharmaceuticals plc stock expected to show significant growthDiscover high-impact investment opportunities - jammulinksnews.com
How strong is Jazz Pharmaceuticals plc company’s balance sheetDiscover market opportunities others miss - jammulinksnews.com
Why Jazz Pharmaceuticals plc stock attracts strong analyst attentionFree Stock Market Analysis Courses - metal.it
How Jazz Pharmaceuticals plc stock performs during market volatilityGrowth Stock Monitor - metal.it
How Jazz Pharmaceuticals plc stock reacts to Fed policy changesDaily Swing Candidates - metal.it
Is Jazz Pharmaceuticals plc a good long term investmentOverwhelming financial success - PrintWeekIndia
What analysts say about Jazz Pharmaceuticals plc stockSuperior portfolio returns - PrintWeekIndia
Idiopathic Hypersomnia Treatment Market Propelled by Rising - openPR.com
Will Jazz Pharmaceuticals plc stock benefit from AI tech trendsExplosive capital gains - jammulinksnews.com
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 - 富途牛牛
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference - MSN
What drives Jazz Pharmaceuticals plc stock priceUnmatched market performance - Autocar Professional
Jazz Pharmaceuticals plc Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
Jazz Pharmaceuticals Q2 Earnings: Management to Host After-Hours Update on August 5 - Stock Titan
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):